Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07185256 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
A Phase 1 study of Best Vitelliform Macular Dystrophy and ARB, sponsored by Opus Genetics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT07185256 is a Phase 1 study of Best Vitelliform Macular Dystrophy and ARB that is actively recruiting participants, run by Opus Genetics. The registered enrollment target is 10 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07185256, a Phase 1 study of Best Vitelliform Macular Dystrophy and ARB, is actively recruiting participants, sponsored by Opus Genetics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are: Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB. A second question it aims to answer is identification of the most appropriate dose strength of OPGx-BEST1 for clinical development. Evaluate the efficacy of single injection of OPGx-BEST1 in one eye for 5 years post-injection. What medical problems do participants have when taking drug OPGx-BEST1?
Conditions Studied
Interventions
- GENETIC OPGx-BEST1
Study Locations (4)
California
- Children's Hospital Los Angeles - Los Angeles
Florida
- Vitreo Retinal Associates - Gainesville
Ohio
- Cincinnati Eye Institute - Cincinnati
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07185256
The ClinicalTrials.gov registry entry for NCT07185256 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Opus Genetics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Best Vitelliform Macular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which OPGx-BEST1 is the first listed.
NCT07185256 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT07185256 about?
NCT07185256 is a clinical study titled "Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)". The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are: Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for ...
What is the current status of trial NCT07185256?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-09-25. Estimated completion is 2030-08.
What conditions does trial NCT07185256 study?
This clinical trial studies the following conditions: Best Vitelliform Macular Dystrophy, ARB, BVMD, Autosomal-Dominant Bestrophinopathy.
What interventions are being tested in trial NCT07185256?
The interventions under investigation include: OPGx-BEST1 (GENETIC).
Who is sponsoring clinical trial NCT07185256?
This trial is sponsored by Opus Genetics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07185256 being conducted?
This trial has 4 study locations across California, Florida, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Best Vitelliform Macular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.